OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Adimmune OCF Yield % Related Terms
Adimmune OCF Yield % Historical Data
* Premium members only.
The historical data trend for Adimmune's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4142 vs VRTX, REGN, ALNY: OCF Yield % Comparison
For the Biotechnology subindustry, Adimmune's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adimmune OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adimmune's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Adimmune's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adimmune (TPE:4142) has a OCF Yield % of -0.08 as of Jun. 30, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Adimmune and its competitors. According to the industry distribution chart, Adimmune ranks #305 out of 1416 companies in the Biotechnology industry, placing it in the top 21.5%.
Is Adimmune's OCF Yield % too high?
Adimmune's current OCF Yield % is -0.08. Based on the distribution chart, Adimmune ranks #305 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Adimmune has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adimmune ranks #305 out of 1416 companies for OCF Yield %. This places Adimmune in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Adimmune and its competitors. Adimmune's current OCF Yield % is -0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.40, compared to a current price of NT$17.60 — trading 30.7% below its estimated fair value. The current OCF Yield % is -0.08. Adimmune's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Adimmune (TPE:4142), the current OCF Yield % is -0.08 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adimmune (TPE:4142) Overvalued in 2026?
Based on GuruFocus' analysis, Adimmune stock appears to be undervalued.
The current stock price of NT$17.60 is trading 30.7% below its estimated GF Value™ of NT$25.40.
GuruFocus considers Adimmune to be Possible Value Trap.
Key valuation signals for TPE:4142:
OCF Yield %: -0.08
GF Value™: NT$25.40 vs. price of NT$17.60 (30.7% below fair value)
No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
55GF Score
Get the complete analysis for TPE:4142
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4142 has been successfully added to your 
